在化疗基础上加用blinatumomab可降低标准风险儿科B-ALL的复发风险

IF 81.1 1区 医学 Q1 ONCOLOGY
Peter Sidaway
{"title":"在化疗基础上加用blinatumomab可降低标准风险儿科B-ALL的复发风险","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00980-1","DOIUrl":null,"url":null,"abstract":"<p>Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse.</p><p>In this trial, 1,440 children (1–10 years of age) with standard-risk B-ALL with an average (<i>n</i> = 835) or high (<i>n</i> = 605) risk of relapse, based on cytogenetic features and minimal residual disease (MRD) status on completion of induction therapy, were randomly assigned (1:1) to receive two cycles of post-induction (for average-risk patients) or post-consolidation (for high-risk patients) chemotherapy with versus without blinatumomab. Disease-free survival (DFS) was the primary endpoint.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"11 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL\",\"authors\":\"Peter Sidaway\",\"doi\":\"10.1038/s41571-024-00980-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse.</p><p>In this trial, 1,440 children (1–10 years of age) with standard-risk B-ALL with an average (<i>n</i> = 835) or high (<i>n</i> = 605) risk of relapse, based on cytogenetic features and minimal residual disease (MRD) status on completion of induction therapy, were randomly assigned (1:1) to receive two cycles of post-induction (for average-risk patients) or post-consolidation (for high-risk patients) chemotherapy with versus without blinatumomab. Disease-free survival (DFS) was the primary endpoint.</p>\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00980-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00980-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管取得了相当大的进展,但b细胞急性淋巴细胞白血病(B-ALL)仍然是儿童癌症相关死亡的主要原因。现在,来自III期AALL1731试验的数据表明,在化疗中加入CD19 × CD3双特异性T细胞参与者blinatumomab可显著改善具有平均或高风险疾病复发的标准风险B-ALL患者的预后。在这项试验中,1440名患有标准风险B-ALL的儿童(1-10岁),基于诱导治疗完成后的细胞遗传学特征和最小残留疾病(MRD)状态,复发风险平均(n = 835)或高(n = 605),随机分配(1:1)接受诱导后(平均风险患者)或固化后(高风险患者)化疗两个周期,与不使用blinatumomab相比。无病生存期(DFS)是主要终点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL

Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse.

In this trial, 1,440 children (1–10 years of age) with standard-risk B-ALL with an average (n = 835) or high (n = 605) risk of relapse, based on cytogenetic features and minimal residual disease (MRD) status on completion of induction therapy, were randomly assigned (1:1) to receive two cycles of post-induction (for average-risk patients) or post-consolidation (for high-risk patients) chemotherapy with versus without blinatumomab. Disease-free survival (DFS) was the primary endpoint.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信